ClinicalTrials.gg
WithdrawnNCT00760916Updated Jan 30, 2013

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of UT-15C 1 mg and UT-15C 0.25 mg in Pulmonary Hypertension, sponsored by United Therapeutics. Withdrawn at 31 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-01-30.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study stopped prior to subject enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
38th of 44
0 · median 32
Started
2008
with 3 others
Phase 3
14 of 44
1 open now
Registered
10th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 38th largest by enrollment, is one of 4 that started in 2008, is one of 14 in phase 3, and was the 10th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor)or as a monotherapy treatment. Study visits will occur at 4 week intervals for 12 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. At the end of the first 12-weeks, the patient will be un-blinded. Patients will continue with another 12-Week open label portion with visits occuring at 4-week intervals.

Patients who complete all assessments for 24-weeks will also be eligible to enter a 36 month open-label, extension phase study (FREEDOM - EXT).

Read the detailed description

This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor)or as a monotherapy treatment. Study visits will occur at 4 week intervals for 12 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. At the end of the first 12-weeks, the patient will be un-blinded. Patients will continue with another 12-Week open label portion with visits occuring at 4-week intervals.

Patients who complete all assessments for 24-weeks will also be eligible to enter a 36 month open-label, extension phase study (FREEDOM - EXT).

03

Conditions studied

  • Pulmonary Hypertension

Browse trials for

Keywords

  • Pulmonary Arterial Hypertension
04

In context

Pulmonary Arterial Hypertension Reclassified

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 70 years of age, inclusive
  • Body weight at least 50 kilograms
  • PAH that is either idiopathic/familial; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with .
  • Currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days or not currently receiving approved PAH therapy.
  • Previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of PAH.
  • Reliable and cooperative with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Nursing or pregnant.
  • Received a prostacyclin within the past 30 days.
  • PAH due to conditions other than noted in the above inclusion criteria.
  • History of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.
  • Use of an drug within 30 days of Baseline
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    placebo

    Drug: Placebo

  • Active comparator
    UT-15C 0.25 mg

    UT-15C 0.25 mg

    Drug: UT-15C 0.25 mg

  • Active comparator
    UT-15C 1 mg

    UT-15C 1 mg

    Drug: UT-15C 1 mg

  • Active comparator
    UT-15C 5 mg

    UT-15C 5 mg

    Drug: UT-15C 5 mg

Interventions

07

What researchers measure

Primary outcomes

  1. Change in six-minute walk distance from Baseline to Week 12

    Time frame: 12 weeks

Secondary outcomes

  1. Borg Dyspnea Score

    Time frame: 12 weeks

  2. Clinical Worsening Assessment

    Time frame: 12 weeks

  3. Dyspnea Fatigue Index

    Time frame: 12 weeks

  4. Symptoms of PAH

    Time frame: 12 weeks

  5. World Health Organization (WHO) Functional Class

    Time frame: 12 weeks

  6. Trough 6-Minute Walk Distance

    Time frame: 12 weeks

  7. Trough Borg Dyspnea Score

    Time frame: 12 weeks

  8. Pro-B-type natriuretic peptide (Pro-BNP)

    Time frame: 12 weeks

  9. Optional hemodynamic parameters

    Time frame: 12 weeks

  10. Adverse events

    Time frame: 12 weeks

  11. Clinical Laboratory parameters

    Time frame: 12 weeks

  12. Electrocardiogram findings

    Time frame: 12 weeks

08

Study locations

31 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • West Los Angeles VA Healthcare Center
    Los Angeles, California 90073, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Stanford University
    Stanford, California 94305, United States
  • Pulmonary Hypertension Clinic
    Aurora, Colorado 80045, United States
  • University of Iowa Health Care
    Iowa City, Iowa 52242, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Washington University Hospital
    St. Louis, Missouri 63110, United States
  • Weill Cornell Medical Center
    New York, New York 10021, United States
  • Columbia Presbyterian Medical Center
    New York, New York 10032, United States
  • Mary M Parkes Center for Asthma, Allergy and Pulmonary Care - University of Rochester
    Rochester, New York 14643, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Lagacy Clinic Northwest
    Portland, Oregon 97210, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • University of Texas Southwestern
    Dallas, Texas 75235, United States
  • Intermountain Medical Center
    Murray, Utah 84157-7000, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • St. Vincent's Hospital
    Sydney, New South Wales, Australia
  • Prince Charles Hospital
    Brisbane, Australia
  • The Alfred Hospital
    Melbourne, Australia
  • Instituto Nacional de Cardiologia
    Mexico City, DF 14080, Mexico
  • Unidad de Investigacion Clinica en Medicina (UDICEM)
    Monterrey, Mexico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 26, 2008
Start
Dec 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Last update
Jan 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00760916
First posted
Sep 26, 2008
Start date
Dec 2008
Primary completion
Jan 2009
Completion
Jan 2009
Last update
Jan 30, 2013

Study contacts

Kevin Laliberte, PharmD
study director · United Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion